Core Viewpoint - Kingmed Diagnostics (SH 603882, closing price: 29.02 yuan) announced on October 29 that the share reduction plan by Guochuang Kaiyuan, disclosed on July 9, 2025, has resulted in no shares being reduced during the plan period, which has now expired [1] Company Summary - For the fiscal year 2024, Kingmed Diagnostics reported that its revenue composition is as follows: third-party medical diagnostics accounted for 92.17%, while other businesses made up 7.83% [1] - As of the report date, Kingmed Diagnostics has a market capitalization of 13.4 billion yuan [1]

Group 1 - The Fourth Global Digital Trade Expo opened in Hangzhou, where Dean Diagnostics signed a strategic cooperation agreement with Hangzhou Data Group to co-build a trusted data space for the city [1] - The collaboration aims to create advanced and secure infrastructure for the trusted data space, explore market-oriented data allocation mechanisms, and promote efficient data circulation to enhance the regional digital economy [1][2] - Dean Diagnostics will leverage its high-quality data resources in the medical diagnostics field to establish a trusted data sub-space for the industry, facilitating compliant data circulation and commercial applications [1][2] Group 2 - Dean Diagnostics has developed high-quality data sets across various fields, including oncology, infections, chronic diseases, and maternal and child health, based on over 20 years of service to more than 22,000 medical institutions [2] - The company plans to transition from a data provider to a data operator and value co-creator, establishing a closed-loop ecosystem of "data-service-application" [2] - The launch of the "Smart Inspection Link - Integrated Management Platform for Regional Testing/Pathology" aims to address challenges in regional healthcare, enhancing digital capabilities in grassroots medical services [3]

Core Viewpoint - The strategic partnership between Dian Diagnostics and Hangzhou Data Group aims to establish a trusted data space in Hangzhou, focusing on the efficient circulation of data elements and promoting high-quality development of the regional digital economy [1][2]. Group 1: Strategic Collaboration - Dian Diagnostics signed a strategic cooperation agreement with Hangzhou Data Group to co-build a trusted data space infrastructure in Hangzhou [1]. - The collaboration will leverage Dian Diagnostics' extensive medical testing data to create a compliant trading platform for medical data elements [2]. - The partnership aims to develop high-quality medical data sets and AI medical products, enhancing public health monitoring services for government departments [2]. Group 2: Data Utilization and Innovation - Dian Diagnostics plans to transition from a data provider to a data operator and service enabler, creating a closed-loop ecosystem of "data-service-application" [3]. - The company will enhance AI model optimization in areas such as auxiliary diagnosis and health management through deep operation of medical data assets [3]. - The initiative aims to integrate medical data with digital technology and public services, contributing to Hangzhou's goal of becoming a "digital health capital" [3].